Lombard Medical Technologies: Registration statement filed ahead of proposed IPO

LONDON, UNITED KINGDOM--(Marketwired - Mar 11, 2014) -

                 Lombard Medical Technologies PLC
               ("Lombard Medical" or "the Company")

    Lombard Medical, Inc. files registration statement with SEC
           ahead of proposed IPO on NASDAQ Global Market


London, UK and Irvine, CA, 11 March, 2014 - Lombard Medical
Technologies PLC (AIM: LMT), the specialist medical device company
focused on Endovascular Aortic Repair ("EVAR") of abdominal aortic
aneurysms ("AAAs"), announced today that Lombard Medical, Inc. has
filed a registration statement on Form F-1 with the U.S. Securities and
Exchange Commission ("SEC") relating to a proposed initial public
offering of its ordinary shares. The number of shares to be offered and
the price range for the offering have not yet been determined.

The Company has reserved the ticker "EVAR" for its listing on the
NASDAQ Global Market. In connection with the NASDAQ listing, Lombard
Medical will also delist its ordinary shares from AIM, a market of the
London Stock Exchange and complete a change of domicile, with Lombard
Medical, Inc., a Cayman Islands corporation, becoming the holding
company for the group.

Lombard Medical intends to use proceeds from the proposed NASDAQ
offering to expand its direct sales force in the United States and
develop new products to treat complex vascular disease, including a
stent graft to treat aneurysms in the thoracic aorta. The remaining
proceeds will be used for working capital and for general corporate
purposes.

Jefferies LLC and Barclays Capital Inc. are acting as joint
book-running managers or the proposed offering, and BTIG, LLC is acting
as co-manager.

The proposed offering of these securities will be made only by means of
a prospectus. When available, copies of the preliminary prospectus
relating to the offering may be obtained from Jefferies LLC, Equity
Syndicate Prospectus Department, by email at
 Prospectus_Department@Jefferies.com , by phone at 877-547-6340 or by
mail at 520 Madison Avenue, 2nd Floor, New York, NY 10022 or Barclays
Capital Inc., c/o Broadridge Financial Solutions, by email at
 Barclaysprospectus@broadridge.com , by phone at 888-603-5847 or by mail
at 1155 Long Island Avenue, Edgewood, NY 11717.

A registration statement relating to these securities has been filed
with the SEC but has not yet become effective. These securities may
not be sold nor may offers to buy be accepted prior to the time the
registration statement becomes effective.

This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there by any sale of these
securities in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.     -Ends-


For further information:

Lombard Medical Technologies PLC             Tel: +44 (0)1235 750 800
Simon Hubbert, Chief Executive Officer
Ian Ardill, Chief Financial Officer
Canaccord Genuity Limited (Nomad)            Tel: +44 (0)20 7523 8350
Lucy Tilley / Henry Fitzgerald O'Connor /
Dr Julian Feneley

FTI Consulting (UK)                          Tel: +44 (0)20 7831 3113
Simon Conway / Stephanie Cuthbert /
Victoria Foster Mitchell

Life Capital Partners, LLC (US)              Tel: +1 (949) 370-8500
Matt Clawson


About Lombard Medical

Lombard Medical Technologies PLC (AIM: LMT) is a medical device company
focused on device solutions for the $1.4 billion per annum abdominal
aortic aneurysm ("AAA") repair market. The Company's lead product,
Aorfix, is an endovascular stent graft which has been specifically
designed to solve the problems that exist in treating complex tortuous
anatomy, which is often present in advanced AAA disease. The Company is
headquartered in Oxfordshire, England with US operations in Irvine, CA.


FORWARD-LOOKING STATEMENTS

This announcement may contain forward-looking statements that reflect
the Company's current expectations regarding future events, including
the commercialization and regulatory clearance of the Company's
products, the Group's liquidity and results of operations, as well as
the Group's future capital raising activities. Forward-looking
statements involve risks and uncertainties. Actual events could differ
materially from those projected herein and depend on a number of
factors, including the success of the Company's research and
development and commercialization strategies, the uncertainties related
to the regulatory process and the acceptance of the Company's products
by hospitals and other medical professionals.

                    This information is provided by RNS
          The company news service from the London Stock Exchange

END